*If You Own CPRX, CRBP, NRZ Then Click Here to Join Our Community Of Traders
The Market Signal was created as a platform to help investors, if you own (NASDAQ:CPRX), (NASDAQ:CRBP) or (NYSE:NRZ) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.
https://themarketsignal.com/Free-Report/NOW
(Click the link above or copy, paste and hit enter in your browser for your report)
Catalyst Receives Approval From Health Canada For Firdapse(R) in Treatment of LEMS
https://themarketsignal.com/Free-Report/CPRX
(Click the link above or copy, paste and hit enter in your browser for your report)
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) is a popular stock on Robinhood and it has a market capitalization of $418.88 million. The company announced that Health Canada had approved Firdapse(R) use in the treatment of Lambert-Eaton Myasthenic Syndrome patients in Canada. The Canadian regulatory agency approved the drug under the Priority Review. Catalyst had submitted a marketing application to Health Canada that included efficacy and safety data from its previous clinical studies that evaluated Firdapse(R) in the treatment of LEMS patients.
Data from the studies were used in supporting the New Drug Submission (NDA) to the regulatory agency. The FDA and the European Commission approved Firdapse(R) in 2018 and 2009 respectively for the treatment of LEMS.
Corbus Pharmaceuticals Posts net loss of $38.1 million in Q2 2020
https://themarketsignal.com/Free-Report/CRBP
(Click the link above or copy, paste and hit enter in your browser for your report)
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) is also another popular Robinhood Stock that is currently bullish and its market cap is $479.16 million. The company reported a net loss of $38.1 or $0.52 per diluted share in Q2 2020 compared to a net income of $2.2 million or $0.03 per share in Q2 2019. Revenue in the quarter dropped by around $28.8 million to around $0.3 million which was due to the licensing payment of 27 million that the company had received from Kaken Pharmaceuticals in march last year.
The company has completed enrolment of participants in its DETERMINE third phase study assessing the safety and efficacy of lenabasum in the treatment of dermatomyositis. Topline results from the study are expected in Q4 2021.
New Residential Investment Reports Net Loss Of $8.9 Million In Q2 2020
https://themarketsignal.com/Free-Report/NRZ
(Click the link above or copy, paste and hit enter in your browser for your report)
Another bullish popular Robinhood stock is New Residential Investment Corp (NYSE:NRZ) whose market capitalization is $3.35 billion. The company has reported its financial results for the quarter ended June 30, 2020. Net loss in the quarter was $8.9 million or $0.02 per diluted share while core earnings were $140.2 million or $0.34 per common share. The company returned $41.6 million to shareholders in dividends or $0.1 per share and ended the quarter with $1.013 billion in cash.
Recently Moody's Investor Service announced the completion of a periodic rating review of New Residential Investment and other ratings related to the same unit. Moody's has been conducting the period review since 2019.
Please email or contact us for any edits or errors relating to this stock market news.
If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market, and other Stock Market news.
We will get back to you within 24 hours.
COMTEX_369170961/2700/2020-08-10T10:26:46
Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.
